Derma Sciences, Inc. (DSCI) Announces Record Revenues For The 2013 Fourth Quarter And Full Year, Introduces 2014 Revenue Guidance, Provides Update On DSC127 Phase 3 Clinical Trials
1/16/2014 6:24:22 AM
Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that total revenue for the full year ended December 31, 2013 is expected to be $79.7 million, up 7.7% compared with 2012. Advanced wound care (AWC) revenue for the fourth quarter of 2013 is expected to be $9.4 million, up 22.5% compared with the fourth quarter of 2012, and full year 2013 AWC revenue is expected to be $33.9 million, up 36.6% compared with 2012. Derma Sciences expects to report 2013 full financial results on March 14, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by